- Home
- AMRN vs PRLD Comparison
AMRN vs PRLD Comparison
Compare AMRN & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | PRLD |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.9M | 260.2M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMRN | PRLD |
|---|---|---|
| Price | $11.67 | $3.57 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $12.50 | $9.20 |
| AVG Volume (30 Days) | 60.2K | ★ 434.6K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $258.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 39.22 | ★ 73.43 |
| 52 Week Low | $11.25 | $1.17 |
| 52 Week High | $20.90 | $6.83 |
Technical Indicators
Market Signals| Indicator | AMRN | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 25.75 | 32.31 |
| Support Level | N/A | $2.83 |
| Resistance Level | $15.34 | $4.07 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 13.13 | 20.59 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.